Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2015 | Minimal residue disease (MRD) in multiple myeloma

Rafael Fonseca • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) considers how detecting and monitoring minimal residue disease (MRD) in multiple myeloma may inform and tailor therapeutic decisions. Clinically important methods to determine MRD include flow cytometry and next-generation sequencing.

More from Rafael Fonseca

0:57
Optimal sequencing of therapies for transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Dec 2023
1:04
The value of MRD in transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Jan 2024
2:10
DRd versus VRd in patients with MM: a real-world retrospective analysis
Rafael Fonseca • 9 Dec 2023
1:52
Secondary cytogenetic abnormalities in MM: prognostic value of chromosome 1q gain vs amplification
Rafael Fonseca • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals